Michael Magdy Farag Abdelmalak <br/><br/>
A pharmaceutical study on modified drug delivery systems containing a short acting drug /  
 دراسة صيدلية عن نظم توصيل معدلة تحتوى على عقار قصير المفعول 
Michael Magdy Farag Abdelmalak ; Supervised Soad A. Yehia , Nevine S. Abdelmalak 
 - Cairo :   Michael Magdy Farag Abdelmalak ,   2017 
 - 185 P. :   charts , facsimiles ;   25cm 
<br/><br/>Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics 
<br/><br/> Zaleplon is a hypnotic drug indicated for the short term management of insomnia for sleep induction. Also it has shown efficacy in treatment of middle of night insomnia without hangover effects. Zaleplon undergoes an extensive hepatic first pass metabolism leaving only 30% systemically available. Its elimination half-life is I hour. ZLP belongs to BCS class II with poor solubility and high permeability. Despite being rapidly absorbed after oral adminstration, the poor aqueous solubility of ZLP limits its dissolution rate and delays its onset of action. The best achieved formula of chaper I FM5 showed optimum mucoadhesion strength (1507.12±62.238 mcg/cm²) and controlled release profile (Q₃hr= 29.06%±0.73% and Q₁₂hr= 87.24%±1.71%) with desirability  0.7 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>bi-layered chronopatches  Pulsatile release  Zaleplon